Search...
/
The Fly Cast
Press play to listen
Competitive Advantages
Risks
Competitive Advantages
Proprietary ADAPT® Tissue Technology: Anteris's unique ADAPT® tissue process eliminates glutaraldehyde, aiming to prevent calcification and enhance the durability and hemodynamics of their heart valves.
Superior Hemodynamic Performance: Clinical trials have consistently demonstrated that the DurAVR™ THV exhibits excellent hemodynamic profiles, including large effective orifice areas and low mean gradients, often surpassing traditional TAVR valves.
Potential for Enhanced Durability: The ADAPT® technology promises a longer-lasting heart valve solution, which is a critical advantage, especially for younger and more active patients seeking a durable TAVR option.
Risks
Clinical Trial Outcomes Risk: The success or failure of their ongoing and future clinical trials for the DurAVR heart valve directly impacts regulatory approval and commercial viability.
Regulatory Approval Pathway Risk: Obtaining necessary regulatory approvals (e.g., FDA, CE Mark) is a complex, costly, and uncertain process that can be delayed or denied, preventing market access.
Market Adoption and Commercialization Risk: Even with regulatory approval, there is no guarantee of widespread market adoption by physicians and hospitals, or favorable reimbursement, leading to potential commercialization failure.
Over a week ago
Jul 1, 5:14 PM
Jun 8, 6:05 AM
May 15, 4:51 AM
May 5, 6:28 AM
Apr 28, 6:28 AM
Mar 24, 3:38 PM
Mar 12, 7:34 AM
Mar 11, 6:56 AM
Feb 26, 6:01 PM
Feb 23, 9:20 AM
Jan 21, 6:04 AM
Jan 20, 4:06 PM
Jan 2, 5:20 PM
Nov 26, 4:36 PM
Nov 17, 6:08 AM
Nov 3, 7:17 AM
Oct 28, 6:18 PM
Oct 27, 5:47 PM
Oct 27, 8:48 AM
Oct 15, 9:22 AM
